Back to top anchor

Development of a human oligodendrocyte platform for multiple sclerosis

Year:
2025
Duration:
36 months
Approved budget:
$400,000.00
Researchers:
Dr Amy McCaughey-Chapman
,
Professor Bronwen Connor
,
Dr Jennifer Pereira
Host:
The University of Auckland
Health issue:
Neurological (CNS)
Proposal type:
Emerging Researcher First Grant
Lay summary
Multiple sclerosis (MS) is a chronic, autoimmune neurological disorder affecting 1:1,000 New Zealanders. Oligodendrocytes are cells that produce an insulating sheath called myelin which is required for efficient neuron-to-neuron communication. Oligodendrocytes and myelin are attacked in MS and this leads to the accumulated disability seen in MS. Promoting the ability for oligodendrocytes to re-myelinate affected neurons has potential as a disease-modifying treatment for MS. I have established novel technology that allows the generation of adult human oligodendrocytes from human skin cells. This research will use this technology to develop a human oligodendrocyte model of MS and generate the first NZ-based MS skin cell repository. This research will enable the future identification of therapeutic targets and the testing of treatments with improved clinical translation. It also has potential as a disease-modifying treatment for MS. Together our research will contribute to the greater MS research field and ultimately benefit the MS community.